- Chair: Guido Pauli, Ph.D.
- Introductions and opening remarks. D. Craig Hopp, Ph.D.
- Overview of network pharmacology. Peter Sorger, Ph.D.
Discussion Point #1: How can the strategies of network pharmacology applied to natural products provide:
- Better understanding of the overlapping biologic pathways and targets that result in development and persistence of chronic conditions (especially pain)?
- Characterization of natural products, either known or novel, singly or in combination, with potential to modulate biological networks?
Discussion Point #2: What are the factors to consider when applying this approach to specific conditions versus more agnostic and “exploratory” topics including developing broader data sets of bio-activity for a large array of natural products (e.g. LINCS)?
Tools to unravel complex mechanisms of action for natural products. John MacMillan, Ph.D.
Discussion Point #3: How can these techniques help identify “biologic signatures” that might ultimately be helpful in clinical studies of natural products?
Barriers for implementation in the natural products community. Roger Linington, Ph.D.
Discussion Point #4: Considering the requirements of expertise and resources along the continuum from single omics to multi omics through multi-scale, systems level modeling, where is the field of natural products research best positioned to make significant advances as it relates to network pharmacology?